| 王卉卉,刘 颖,李爱英,张 玮,张 立.替雷利珠单抗注射液联合白蛋白紫杉醇和卡铂对晚期NSCLC患者肠道菌群和SII、PNI的影响[J].,2024,(2):338-342 |
| 替雷利珠单抗注射液联合白蛋白紫杉醇和卡铂对晚期NSCLC患者肠道菌群和SII、PNI的影响 |
| Effects of Telizumab Injection Combined with Albumin Paclitaxel and Carboplatin on Intestinal Flora, SII and PNI in Patients with Advanced NSCLC |
| 投稿时间：2023-08-23 修订日期：2023-09-18 |
| DOI：10.13241/j.cnki.pmb.2024.02.026 |
| 中文关键词: 替雷利珠单抗 白蛋白紫杉醇 卡铂 晚期 非小细胞肺癌 肠道菌群 SII PNI |
| 英文关键词: Teralizumab Injection Albumin paclitaxel Carboplatin Advanced Non small cell lung cancer Intestinal flora SII PNI |
| 基金项目:江苏省卫计委科教强卫工程-重点人才基金资助项目（QNRC2016042） |
|
| 摘要点击次数: 133 |
| 全文下载次数: 99 |
| 中文摘要: |
| 摘要 目的：探讨替雷利珠单抗注射液联合白蛋白紫杉醇和卡铂对晚期非小细胞肺癌（NSCLC）患者肠道菌群和预后营养指数（PNI）、全身免疫炎症指数（SII）的影响。方法：选取2020年5月~2023年2月期间在南京市江宁医院及东南大学附属中大医院接受治疗的晚期NSCLC患者115例。根据随机数字表法将患者分为对照组和研究组，各为57例和58例。对照组接受白蛋白紫杉醇和卡铂治疗，研究组在对照组基础上接受替雷利珠单抗注射液治疗。对比两组客观缓解率（ORR）、疾病控制率（DCR）、血清肿瘤标志物[细胞角蛋白19片段（CYFRA21-1）、癌胚抗原（CEA）、糖类抗原125（CA125）]、肠道菌群（双歧杆菌、乳酸杆菌、肠球菌）和SII、PNI，同时观察两组治疗期间不良反应发生情况。结果：研究组ORR（44.83%）、DCR（77.59%）均高于对照组的24.56%、50.88%（P<0.05）。与对照组治疗后相比，研究组CYFRA21-1、CEA、CA125、肠球菌、SII更低，双歧杆菌、乳酸杆菌、PNI更高（P<0.05）。两组不良反应发生率对比未见差异（P>0.05）。结论：替雷利珠单抗注射液联合白蛋白紫杉醇和卡铂治疗晚期NSCLC患者，可提升临床疗效，改善SII、PNI和肠道菌群。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effects of telizumab injection combined with albumin paclitaxel and carboplatin on intestinal flora and prognostic nutritional index (PNI) and systemic immune inflammatory index (SII) in patients with advanced non small cell lung cancer (NSCLC). Methods: 115 patients with advanced NSCLC who were treated in Nanjing Jiangning Hospital and Zhongda Hospital Affiliated to Southeast University from May 2020 to February 2023 were selected. Patients were divided into control group and study group according to the random number table method, 57 cases and 58 cases respectively. Control group was treated with albumin paclitaxel and carboplatin, and study group was treated with tirelizumab injection on the basis of control group. The objective response rate (ORR), disease control rate (DCR), serum tumor markers [cytokeratin 19 fragment (CYFRA21-1), carcinoembryonic antigen (CEA), carbohydrate antigen 125 (CA125)], intestinal flora (bifidobacterium, lactobacillus, Enterococcus), SII and PNI were compared between two groups, and the incidence of adverse reactions during treatment was observed. Results: The ORR (44.83%) and DCR (77.59%) in study group were higher than those in control group (24.56%, 50.88%) (P<0.05). Compared with control group after treatment, CYFRA21-1, CEA, CA125, Enterococcus and SII in study group were lower, and bifidobacterium, lactobacillus and PNI were higher (P<0.05). There was no difference in the incidence of adverse reactions between two groups (P>0.05). Conclusion: Tirelizumab injection combined with albumin paclitaxel and carboplatin in the treatment of patients with advanced NSCLC, which can improve clinical efficacy and improve SII, PNI and intestinal flora. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
